Eagle Pharmaceuticals (EGRX) Reports In-Line Q1 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Eagle Pharmaceuticals (EGRX) Reports In-Line Q1 EPS

Eagle Pharmaceuticals, Inc. Reports First Quarter 2017 Results

May 8, 2017 6:50 AM EDT

-- Bendeka® market share grew to 95% --

-- Bendeka reached $500 million in cumulative sales in Q1 2017, triggering $25 million milestone --

-- Revenue grew 160% year-over-year to $76.8 million --

-- Q1 2017 EPS grew to $1.50 per basic and $1.42 per diluted share --

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq: EGRX) today announced its financial results for the three months ended March 31, 2017. Highlights of and subsequent to the first quarter of 2017 include:

Business Highlights:

... More